Figure 6.

Oncolytic efficacy of mumps viruses in the mouse CT-26-LacZ colon carcinoma tumor model. Balb/c mice (n = 5) were implanted with 5 × 10⁶ CT-26-LacZ cells subcutaneously. Once the tumor volume reached 0.2–0.5 mm³, mice were treated with saline or mumps viruses (10⁶–10⁷ PFU) administered i.v. through by tail vein: (a) MuV-UC-wt (10⁷), (b) rMuV-UC-GFP-10⁶; (c) rMuV-UC-GFP-10⁷; (d) rMuV-UC-Luc (10⁷); or (e) saline. Tumor size was measured using handheld calipers three times a week. Saline versus GFP106, P = 0.6117; Saline versus GFP107, P = 0.0966; Saline versus Luc, P ≤0.0006; Saline versus WT, P≤0.0001 (f) Kaplan–Meier survival curves for the mice are shown in the survival curve. *P = 0.0072 rMuV-UC-wt versus Saline; P = 0.1316 rMuV-UC-Luc versus Saline. GFP, green fluorescent protein.